A Phase 2 Multicenter Double-Blind Randomized Placebo-controlled Study of Safety and Efficacy Of ANG-3070 in Patients with Primary Glomerular Disease and Persistent Proteinuria.

Brief description of study

The purpose of this study is to see if an investigational drug, called ANG-3070, is safe and effective in kidney disease. ANG-3070 is considered investigational because it has not been approved by the U.S. Food and Drug Administration (FDA), or any other Regulatory Agency to treat any medical condition and is not available for sale to the public. This study is being done to find out if study treatment with an investigational drug called ANG3070 taken by mouth daily for 12 weeks is safe and reduces the amount of protein a person is losing in the urine because of their kidney disease. Drugs that reduce the amount of protein in the urine in kidney disease to help reduce further damage to the kidneys.

Clinical Study Identifier: s21-01495

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.